Recombinant Interferon Eye Drops with PVP for Sustained Corneal Contact
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral agents for ocular viral diseases, including those using human interferon, face challenges such as potential viral contamination, low efficacy, and allergic reactions, with existing eye drops requiring frequent application and having short drug-eye cornea contact time, leading to prolonged treatment durations and increased complication rates.
Innovation Solution
Development of eye drops containing recombinant interferon, antihistamine agents, stabilizers, and an anti-oxidizing agent in specific concentrations, combined with a buffer solution, to enhance penetration and provide sustained-release action, thereby prolonging drug-cornea contact time and reducing treatment duration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human interferon is used in eye drops, then antiviral efficacy is improved, but risk of viral contamination increases
Solution Approach 1:
The patent extracts the interferon gene from human cells and transfers it to E. coli bacteria for production. This separation allows the interferon to be produced in a controlled microbial system, eliminating the risk of human viral contamination while maintaining the therapeutic antiviral properties of the interferon molecule.
Solution Approach 2:
The patent uses E. coli bacteria as an intermediary host to produce human interferon. The bacteria serve as a safe intermediate system that can be rigorously controlled and sterilized, acting as a mediator between human medical needs and viral contamination risks, ultimately producing contaminant-free interferon.
2Reliability
If existing eye drop formulations are used, then antiviral action is provided, but drug-eye cornea contact time is short
Solution Approach 1:
The patent creates a composite eye drop formulation combining recombinant interferon with polyvinylpyrrolidone (PVP) as a stabilizer and viscosity-enhancing agent. This composite formulation increases the residence time of the eye drops on the corneal surface, allowing prolonged drug-eye contact time while maintaining antiviral efficacy.
3Reliability
If frequent eye drop application is required, then therapeutic effect is maintained, but treatment duration is prolonged and complication rates increase
Solution Approach 1:
The patent formulates eye drops with extended residence time properties using polyvinylpyrrolidone, enabling the drug to remain in contact with the cornea for prolonged periods. This continuous therapeutic action reduces the frequency of administration needed while maintaining effective antiviral levels, thereby shortening overall treatment duration and reducing complications.
Data Source
AI summary
The invention refers to pharmaceutical industry, specifically to the development of interferon-containing compounds capable to increase their antiviral potency and applicable in ophthalmology for the treatment of viral diseases of the eye. Essence of the invention: eye drops containing recombinant interferon; stabilizer of biological and physicochemical properties; stabilizer of resistance to microbial contamination, anti-oxidizing agent; and buffer solution; under the invention, the eye drops contain antihistamine agents selected from the following group: anthazoline, azelastin, tetryzoline, diphenhydramine hydrochloride; as stabilizers of biological and physicochemical properties, the product contains agents selected from the following group: low-molecular polyvinyl pyrrolidone, Macrogol 400-12000, propylene glycol; as a stabilizer of resistance to microbial contamination the drops contain agents selected from the group: Nipasol, sorbic acid, boric acid. In addition, the eye drops contain sodium chloride and/or sodium acetate with the following component concentrations per ml of the solution: As an anti-oxidizing agent, the eye drops contain Trilon B and/or buthylhydroxytoluene in the amount of 0.0001-0.1 g per ml of the solution. The eye drops contain recombinant interferon selected from the group: alpha-, beta-, gamma-interferon. They also contain acetate borate or phosphate, or borate buffer as a buffer solution.